



# Translating innovative ideas to breakthrough oncology medicines

## CORPORATE PROFILE

IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, the Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.

A major focus of IDEAYA is to exploit the concept of synthetic lethality, a phenomenon whereby the independent loss-of-function of two different genes have no significant effects on cell growth and viability, but when combined results in robust cell death. Synthetic lethality while a longstanding concept in genetic model systems and cancer biology has only recently been translated into a therapeutic reality with the approval of a PARP-inhibitor, olaparib, in BRCA deficient ovarian cancer. IDEAYA will focus on novel synthetic lethal interactions for genetically defined patient populations, exploiting inherent tumor susceptibilities en-route to discovery and development of small-molecule agents to treat major human cancers. Another area of focus for IDEAYA will be to exploit the potential of modulating DNA repair to augment response to immunotherapy. In addition, drug discovery programs will target pathways known to produce an immune suppressed tumor microenvironment, enabling tumors to escape recognition by the host immune system.

### Leadership Team

Yujiro S. Hata, CEO  
Jeffrey Hager, Ph.D., SVP Biology  
Michael, P. Dillon, Ph.D., SVP Drug Discovery  
Timothy J. Smith, SVP Corporate Development

### Scientific Advisors

Alan D'Andrea, M.D., Harvard  
John Petrini, Ph.D. MSKCC  
Trey Ideker, Ph.D., UCSD  
Stephen Kowalczykowski, Ph.D., UCD  
Elizabeth Swisher, M.D., UW  
Richard Ulevitch, Ph.D., Scripps  
Laura Shawver, Ph.D., Cleave  
Paul Reider, Ph.D., Princeton  
Lawrence Fong, M.D., UCSF  
William Sellers, M.D. Harvard

### Board Members

John Diekman, Ph.D., Chairman, 5AM  
Tim Shannon, M.D., Canaan Partners  
Terry Rosen, Ph.D., Arcus Biosciences  
Jeff Stein, Ph.D., Cidara Therapeutics  
Yujiro S. Hata, CEO, IDEAYA  
Peter Worland, Ph.D., Celgene  
Edward Hu, WuXi  
Paul Stone J.D., 5AM

### Investors

5AM Ventures  
Canaan Partners  
Celgene  
WuXi Healthcare Ventures  
Novartis Institutes of Biomedical Research  
Alexandria Real Estate

### Quick Facts

Founded August 2015  
\$46M Series A

### Contact Details

IDEAYA SSF  
7000 Shoreline Court, Suite 350  
South San Francisco, CA 94080

IDEAYA La Jolla  
3033 Science Park Rd., Suite 250  
San Diego, CA 92121

